Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings

Atsuho Morita; Ho Namkoong; Kazuma Yagi; Takanori Asakura; Makoto Hosoya; Hiromu Tanaka; Ho Lee; Takunori Ogawa; Tatsuya Kusumoto; Shuhei Azekawa; Kensuke Nakagawara; Hirofumi Kamata; Makoto Ishii; Koichi Fukunaga; Hiroyuki Ozawa; Naoki Hasegawa

doi:10.2147/IDR.S373783

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings

Infect Drug Resist. 2022 Jul 26:15:4001-4011. doi: 10.2147/IDR.S373783. eCollection 2022.

Authors

Affiliations

¹ Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
² Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
³ Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.

Abstract

Purpose: Amikacin liposome inhalation suspension (ALIS), which efficiently allows amikacin to reach the pulmonary periphery for effect while minimising systemic adverse effects, was recently approved for treating Mycobacterium avium complex (MAC) infections. The international Phase 3 open-label clinical trials showed promising results, contributing to sputum culture conversion, but few studies have examined the efficacy and adverse effects of ALIS using real-world data. We identified the clinical outcome and adverse effects of ALIS in the early phase of treatment, for more effective and safe use in clinical practice.

Patients and methods: The study population consisted of patients with MAC lung disease (MAC-LD), introduced to ALIS therapy after July 2021 at Keio University Hospital due to poor response to multidrug therapy. The sputum smear/culture results, symptoms, adverse effects, and the serum amikacin concentrations of the early phase of ALIS inhalation therapy were examined.

Results: A total of 11 patients (9 women; median age 64.6 years) were included in this study. The median disease duration of MAC-LD was 13.7 years, and all patients exhibited a positive culture at the beginning of ALIS inhalation. Three of the six patients (50.0%) who were initially sputum-smear-positive were confirmed to have become sputum-smear-negative within one month, including one culture conversion. ALIS inhalation therapy caused some adverse effects in nine patients (81.8%); however, no serious systemic adverse effects were observed. The most common adverse effect was hoarseness (72.7%), which mostly occurred around 1 week after initiation. The medians of peak serum amikacin concentrations were 1.4 and 2.3 μg/mL for the first and third inhalations, respectively. Trough serum concentrations just before the third inhalation were <1.2 μg/mL in all patients.

Conclusion: ALIS therapy might be a treatment option for patients with refractory MAC infection with long disease duration and a poor response to guideline-based therapy.

Keywords: ALIS; MAC; Mycobacterium avium complex; NTM; amikacin liposome inhalation suspension; nontuberculous mycobacteria.

Publication types

Case Reports

Grants and funding

This study was funded by AMED (21fk0108621h0001), JSPS Grant-in-Aid for JSPS fellows (21J21344), JSPS Grant-in-Aid for Young Scientists (21K15667), and JAID Clinical Research Promotion Grant, and JST PRESTO (JPMJPR21R7).